ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
Dimitrios63
|
21 |
5.8K |
1 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
21
|
5.8K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
Dimitrios63
|
21 |
5.8K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
21
|
5.8K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
Dimitrios63
|
21 |
5.8K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
21
|
5.8K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AACR Conference Presentation
|
|
Dimitrios63
|
7 |
1.2K |
2 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
7
|
1.2K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
44 |
10K |
1 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
44
|
10K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
44 |
10K |
4 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
44
|
10K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
44 |
10K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
44
|
10K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
44 |
10K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
10K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dimitrios63
|
58 |
14K |
0 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dimitrios63
|
58 |
14K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dimitrios63
|
58 |
14K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
58
|
14K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Dimitrios63
|
58 |
14K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
58
|
14K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
Dimitrios63
|
13 |
4.7K |
4 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
13
|
4.7K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
26 |
8.0K |
2 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
26
|
8.0K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
26 |
8.0K |
2 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
26
|
8.0K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
Dimitrios63
|
26 |
8.0K |
4 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
26
|
8.0K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Update
|
|
Dimitrios63
|
21 |
6.5K |
6 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
21
|
6.5K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Update
|
|
Dimitrios63
|
21 |
6.5K |
3 |
14/10/23 |
14/10/23 |
ASX - By Stock
|
21
|
6.5K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
|
|
Dimitrios63
|
1 |
627 |
7 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
1
|
627
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ATX - Shareholder Newsletter July 2023
|
|
Dimitrios63
|
14 |
4.2K |
4 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
14
|
4.2K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Application for quotation of securities - ATX
|
|
Dimitrios63
|
7 |
1.8K |
5 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
7
|
1.8K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Application for quotation of securities - ATX
|
|
Dimitrios63
|
7 |
1.8K |
3 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
7
|
1.8K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 International Nonproprietary Name Narmafotinib
|
|
Dimitrios63
|
10 |
3.5K |
4 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
10
|
3.5K
|
4
|
|
ASX - By Stock
|
ATX Biotech |
Re:
Industry related information
|
|
Dimitrios63
|
19 |
5.5K |
2 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
19
|
5.5K
|
2
|
|
ASX - By Stock
|
ATX Biotech |
Re:
Industry related information
|
|
Dimitrios63
|
19 |
5.5K |
1 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
19
|
5.5K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
|
|
Dimitrios63
|
24 |
8.1K |
6 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
24
|
8.1K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia receives grant to collaborate with CSIRO
|
|
Dimitrios63
|
16 |
4.1K |
4 |
25/05/23 |
25/05/23 |
ASX - By Stock
|
16
|
4.1K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia receives grant to collaborate with CSIRO
|
|
Dimitrios63
|
16 |
4.1K |
8 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
16
|
4.1K
|
8
|
|
ASX - By Stock
|
RHY |
Re:
Ann: UK CA Mark granted for ColoSTAT
|
|
Dimitrios63
|
98 |
32K |
3 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
98
|
32K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
16 |
4.5K |
6 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
16
|
4.5K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
16 |
4.5K |
4 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
16
|
4.5K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
16 |
4.5K |
8 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
16
|
4.5K
|
8
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports - March 23 Qtr
|
|
Dimitrios63
|
9 |
2.8K |
8 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
9
|
2.8K
|
8
|
|
ASX - By Stock
|
ATX |
Re:
Ann: First Patient Recruited to Cohort 3 of ACCENT Trial
|
|
Dimitrios63
|
9 |
3.0K |
6 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
9
|
3.0K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Dose Escalation Approved in ACCENT Clinical Trial of AMP945
|
|
Dimitrios63
|
9 |
4.3K |
3 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
9
|
4.3K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
17 |
7.0K |
3 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
17
|
7.0K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
17 |
7.0K |
2 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
17
|
7.0K
|
2
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Update to TGA Submission
|
|
Dimitrios63
|
198 |
73K |
5 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
198
|
73K
|
5
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Update to TGA Submission
|
|
Dimitrios63
|
198 |
73K |
7 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
198
|
73K
|
7
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Suspension from Official Quotation
|
|
Dimitrios63
|
69 |
23K |
6 |
05/03/23 |
05/03/23 |
ASX - By Stock
|
69
|
23K
|
6
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Suspension from Official Quotation
|
|
Dimitrios63
|
69 |
23K |
1 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
69
|
23K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ACCENT Trial Recruitment Progress
|
|
Dimitrios63
|
17 |
7.0K |
3 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
17
|
7.0K
|
3
|
|
ASX - By Stock
|
RHY |
Re:
Process for Colostat to be included in MBS (Medicare)
|
|
Dimitrios63
|
4 |
1.5K |
2 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
4
|
1.5K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Reinstatement to official quotation
|
|
Dimitrios63
|
12 |
6.7K |
9 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
12
|
6.7K
|
9
|
|
ASX - By Stock
|
RHY |
Re:
Commercialisation of Colostat
|
|
Dimitrios63
|
22 |
4.9K |
5 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
22
|
4.9K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports - December 2022
|
|
Dimitrios63
|
4 |
1.4K |
8 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
4
|
1.4K
|
8
|
|
Charts
|
RHY |
Re:
RHY charts
|
|
Dimitrios63
|
80 |
44K |
1 |
24/01/23 |
24/01/23 |
Charts
|
80
|
44K
|
1
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Market Update
|
|
Dimitrios63
|
9 |
3.0K |
3 |
15/12/22 |
15/12/22 |
ASX - By Stock
|
9
|
3.0K
|
3
|
|
ASX - By Stock
|
RHY |
Re:
Ann: RHY 2022 AGM Presentation
|
|
Dimitrios63
|
21 |
7.1K |
0 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
21
|
7.1K
|
0
|
|
ASX - By Stock
|
RHY |
Re:
Ann: RHY 2022 AGM Presentation
|
|
Dimitrios63
|
21 |
7.1K |
2 |
03/12/22 |
03/12/22 |
ASX - By Stock
|
21
|
7.1K
|
2
|
|